Title

Allogeneic Mesenchymal Stem Cells in Osteoarthritis
A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    60
This trial is planed to study if allogeneic mesenchymal stem cells would be safe and beneficial in osteoarthritis of knee joint. This is a double blind study. Different doses of stem cells will be used in this study.
Study Started
Nov 30
2011
Primary Completion
Nov 30
2014
Study Completion
Nov 30
2014
Last Update
May 12
2016
Estimate

Biological Ex- vivo cultured adult allogeneic MSCs

Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan

Biological Plasmalyte-A

Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan

Ex- vivo cultured adult allogeneic MSCs Experimental

Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan

Plasmalyte-A Placebo Comparator

Single intraarticular dose of 2ml Plasmalyte

Criteria

Inclusion Criteria:

Males or females in the age 40 - 70 years (both inclusive)
Radiographic evidence of grade 2 to 3 osteoarthritis based on the Kellgren and Lawrence radiographic criteria.
History of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics.
Self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs.
Patients who have been on stable medication which may be NSAIDs / Opioid or opiate analgesics, for the past three months.
Female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study
Ability to provide written informed consent.

Exclusion Criteria:

Prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
History of surgery, or major trauma to the study joint
Arthroscopy on the study joint in the previous 12 months
Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination
Patients who had received intraarticular steroids or hyaluronan within the last three months.
Infections in or around the knee.
Patients awaiting a replacement knee or hip joint
Patients with other conditions that cause pain
Patients with deformity of the knee joint.
Significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices
Patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis
Other pathologic lesions on x-rays of knee
Positive hepatitis B surface antigen, hepatitis C antibody test, Anti human immunodeficiency virus (HIV) antibody test, or RPR
History of Bleeding disorders
Known hypersensitivity to Hyaluronan products or animal sera
For women of child-bearing potential: positive pregnancy test or lactating [Females who are planning pregnancy within next one year should be excluded]
No Results Posted